SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Alexion Pharmaceuticals, Inc. (Nasdaq – ALXN)

BALA CYNWYD – December 14, 2020 /Access Wire/ – Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) (Nasdaq – ALXN) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the agreement to be acquired by AstraZeneca PLC (“AstraZeneca”). Under the terms of the agreement, Alexion shareholders will receive $60.00 per share in cash and 2.1243 AstraZeneca American Depositary Shares (“ADSs”) (each ADS representing one-half of one ordinary share of AstraZeneca) for each share of Alexion common stock they hold, implying a total consideration of $175 per share to Alexion shareholders.

The investigation concerns whether the Alexion Board breached its fiduciary duties to shareholders by failing to conduct a fair process and whether AstraZeneca is paying too little for the Company.

If you own shares of Alexion stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 805, Bala Cynwyd, PA 19004, or call toll free 855-576-4897.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.